Limb-Girdle Muscular Dystrophy Treatment Market Size, Share, Patient Pathway, Pipeline, Competitive Landscape and Forecast, 2026–2035

Limb-Girdle Muscular Dystrophy Treatment Market Size and Forecast

The global limb-girdle muscular dystrophy treatment market was valued at USD 631.7 million in 2025 and is projected to reach USD 854.74 million by 2035, growing at a CAGR of 3.07% during 2026–2035. Limb-girdle muscular dystrophy, or LGMD, is a genetically diverse group of disorders characterized by progressive weakness of muscles around the shoulders, hips, upper arms and thighs. Cardiac and respiratory involvement varies by subtype. Modern nomenclature distinguishes autosomal-dominant forms with a D designation and autosomal-recessive forms with an R designation, while legacy labels such as LGMD1 and LGMD2 remain common in clinical and commercial literature.

As of September 16, 2026, supportive and complication-directed care still generated the commercial market. Physical and occupational therapy, mobility support, respiratory care, cardiac management, pain treatment and selected medications are used according to the patient’s phenotype. No disease-modifying therapy had yet received approval for LGMD. The most important near-term change was FDA Priority Review of BridgeBio’s oral BBP-418 for LGMD2I/R9, with a target action date of November 27, 2026. A positive decision would create the first approved subtype-specific treatment and change the market’s pricing, diagnosis and referral structure.

Key Highlights

• The market is forecast to add USD 203.57 million between 2025 and 2035.
• Autosomal-recessive LGMD forms represented an estimated 56% of 2025 revenue, equal to USD 353.75 million.
• Medications used for symptoms and complications accounted for an estimated 52%, or USD 328.48 million, in 2025.
• Hospitals and neuromuscular centers generated an estimated 62% share, equal to USD 391.65 million.
• North America led with an estimated 39%, or USD 246.36 million, supported by genetic testing, specialist centers and the leading late-stage pipeline.
• Europe held an estimated 30% share, equal to USD 189.51 million, with strong registries, natural-history research and gene-therapy development.
• FDA review of BBP-418 and early clinical data for ATA-200 made 2026 a pivotal year for the first transition from supportive management to subtype-specific therapy.

Limb-Girdle Muscular Dystrophy Treatment Market Scope

The Market Is Moving from a Syndrome Label to Genotype-Specific Care

LGMD is not one disease. It includes disorders caused by variants in FKRP, CAPN3, DYSF, SGCA, SGCB, SGCG, SGCD, ANO5 and other genes. Disease course, cardiac risk, respiratory decline, ambulatory loss and treatment eligibility differ across subtypes. Commercial forecasting based only on the broad LGMD label can therefore overstate the addressable population for any single product.

Genetic confirmation is becoming the gatekeeper for treatment. A patient considered for BBP-418 must have an eligible FKRP-related phenotype. ATA-200 targets gamma-sarcoglycan deficiency in LGMD2C/R5, while SRP-9003 is designed for beta-sarcoglycan deficiency in LGMD2E/R4. Each therapy requires a distinct patient-finding strategy, natural-history comparator and outcome framework.

This shift increases the value of neuromuscular referral networks, genetic counseling, variant interpretation and registries. It also exposes a diagnosis gap. Patients can remain under nonspecific muscular-dystrophy labels, receive inconclusive older testing or live far from centers able to perform gene panels and interpret variants. Commercial launch readiness depends on finding confirmed patients before approval rather than waiting for demand to appear afterward.

Market Growth Drivers

BBP-418 could create the first commercial disease-modifying category

BBP-418 is an oral glycosylation-substrate therapy designed to increase residual FKRP enzyme function and restore alpha-dystroglycan glycosylation. BridgeBio reported that the Phase 3 FORTIFY interim analysis met its prespecified endpoints. On May 27, 2026, the FDA accepted the new drug application and granted Priority Review, assigning a November 27, 2026 target action date.

BridgeBio estimates that around 7,000 people live with LGMD2I/R9 and other addressable alpha-dystroglycanopathies in the United States and Europe. If approved, an oral therapy could reach a broader clinical population than an intravenous gene therapy because it avoids vector eligibility and one-time infusion logistics. Pricing, payer evidence, pediatric expansion and European access will determine the revenue effect after regulatory review.

Gene therapy expands the long-term pipeline but raises safety and delivery demands

AAV gene therapy aims to deliver a functional copy of a missing or defective muscle protein gene. Programs target individual sarcoglycanopathies and FKRP-related disease. The therapeutic logic is strong, but systemic delivery to skeletal, respiratory and cardiac muscle requires high vector exposure and careful immune, liver and manufacturing management.

Atamyo’s ATA-200 uses an AAV vector carrying the human SGCG transgene for LGMD2C/R5. In May 2026, the company presented early results from the first treated patients. These data support continued development but remain early, open-label evidence. Sarepta’s SRP-9003 targets beta-sarcoglycan deficiency, while AskBio’s AB-1003 targets FKRP-related LGMD2I/R9. Program-specific safety and regulatory status must be assessed rather than extrapolated across the class.

Supportive care remains essential across every subtype

Even after a disease-modifying therapy enters the market, patients will require physical therapy, contracture management, mobility assistance, pulmonary surveillance, non-invasive ventilation and cardiac monitoring. Some subtypes carry cardiomyopathy or arrhythmia risks that require specialist follow-up. Advanced therapy is likely to add to the care pathway before it replaces existing services.

Multidisciplinary neuromuscular centers are positioned to coordinate diagnosis, baseline functional assessment, treatment selection and longitudinal monitoring. This concentrates market access in a limited number of high-expertise sites and makes referral education an important commercial function.

Market Barriers and Development Risks

Small, genetically fragmented populations make trials difficult. A therapy may target only one LGMD subtype, and eligible patients can be distributed across many countries. Variation in age, genotype, ambulatory status and disease stage increases outcome variability. Sponsors need international sites, natural-history data and endpoints sensitive enough to detect change over a practical trial period.

Gene-therapy safety is a material constraint. Systemic AAV programs require monitoring for liver injury, immune responses, thrombocytopenia and other serious events. Prior safety events in neuromuscular gene therapy have increased regulatory scrutiny of dose, manufacturing consistency, patient selection and post-treatment management. A platform designation or orphan designation does not establish safety or efficacy for a specific product.

Manufacturing creates another bottleneck. One-time gene therapies require high-quality vector production, potency testing, comparability and long-term follow-up. Scale is challenging even for small populations because doses can be large. Oral small molecules face fewer administration constraints, but they still require chronic adherence, pharmacovigilance and proof that biomarker improvement translates into durable clinical benefit.

Reimbursement will be genotype and evidence specific. Payers may request confirmed molecular diagnosis, baseline function, specialist prescribing and response monitoring. Outcomes-based arrangements may be considered for high-cost therapies, but LGMD’s slow and variable course complicates contract design.

Market Segmentation Analysis

By Inheritance Pattern and Legacy Type

Autosomal-recessive forms, historically grouped as LGMD type 2 and now designated LGMDR subtypes, accounted for an estimated 56% of 2025 market revenue, equal to USD 353.75 million. This group includes calpainopathy, dysferlinopathy, FKRP-related LGMD and sarcoglycanopathies. It attracts most current drug-development activity because several subtypes have clearly defined loss-of-function mechanisms suited to gene replacement or substrate therapy.

Autosomal-dominant forms, historically grouped as LGMD type 1 and now designated LGMDD subtypes, represented an estimated 44%, or USD 277.95 million. Dominant disease mechanisms can involve toxic or interfering proteins, making straightforward gene replacement less applicable in some subtypes. Current revenue is therefore weighted toward symptom management, rehabilitation and complication monitoring.

By Treatment Modality

Medications used for symptoms and complications generated an estimated 52% of 2025 revenue, equal to USD 328.48 million. This segment includes drugs used for pain, inflammation, cardiac disease, respiratory complications and other patient-specific needs. These products are not approved to reverse the underlying LGMD mechanism.

Rehabilitation, respiratory support and other non-drug management accounted for an estimated 43%, or USD 271.63 million. Physical and occupational therapy, mobility support, orthotics, assisted ventilation and cardiac surveillance form the durable care base. Revenue growth is steady because these services remain necessary as disease progresses.

Gene therapy and other advanced investigational treatment activity represented an estimated 5%, equal to USD 31.59 million, in 2025. This figure reflects trial-related treatment infrastructure, specialist services and early-access activity rather than commercial sales of an approved LGMD gene therapy. Its share could change rapidly after a first approval, but pipeline value should not be counted as marketed-drug revenue.

By End User

Hospitals and neuromuscular centers held an estimated 62% of 2025 revenue, equal to USD 391.65 million. These centers provide genetics, neurology, cardiology, pulmonology, rehabilitation and clinical-trial access. Advanced therapies will reinforce their role because patient selection and monitoring require specialized teams.

Specialty outpatient and rehabilitation clinics represented an estimated 27%, or USD 170.56 million. They provide longitudinal therapy, functional assessment, orthotics and symptom management closer to the patient’s home. Home care and other settings accounted for 11%, equal to USD 69.49 million, driven by respiratory equipment, mobility support and caregiver-assisted management.

Regional and Country-Level Analysis

North America

North America led with an estimated 39% share in 2025, equal to USD 246.36 million. The United States represented 34% of global revenue, or USD 214.78 million, supported by specialist neuromuscular centers, broad genetic testing, rare-disease incentives and the leading regulatory review for BBP-418. Canada contributed an estimated 3%, equal to USD 18.95 million, with the remainder generated across Mexico and other regional demand.

The United States is the principal launch market for the first subtype-specific therapy, but patient finding will determine uptake. Confirmed FKRP genotypes, treatment-center readiness and payer criteria will be more important than total muscular-dystrophy prevalence.

Europe

Europe accounted for an estimated 30% share, or USD 189.51 million, in 2025. Germany generated an estimated 6% of global revenue, equal to USD 37.90 million; the United Kingdom held 5%, or USD 31.59 million; France contributed 4.5%, equal to USD 28.43 million; and Italy represented 3.5%, or USD 22.11 million.

France is strategically important through Généthon and Atamyo’s AAV research. The UK and northern Europe contribute registries and natural-history studies, while Germany represents a high-value rare-disease treatment market. National health-technology assessment, cross-border genetic testing and center accreditation will shape post-approval access.

Asia-Pacific

Asia-Pacific held an estimated 22%, equal to USD 138.97 million, and is expected to grow fastest through 2035. China represented an estimated 6% of global revenue, or USD 37.90 million; Japan held 5%, equal to USD 31.59 million; India contributed 3%, or USD 18.95 million; and Australia accounted for 2%, equal to USD 12.63 million.

The region has a large undiagnosed population, but access to molecular testing and specialist neuromuscular care varies. Japan and Australia have mature rare-disease systems, while China and India offer larger patient-finding potential with greater access variability. Local regulatory submissions and ethnicity-inclusive natural-history data will influence advanced-therapy adoption.

Latin America

Latin America represented an estimated 5% of 2025 revenue, equal to USD 31.59 million. Brazil is the leading regional market through university neuromuscular programs and genetic services, followed by Mexico and Argentina. Diagnosis delays, limited reimbursement for genetic testing and travel to specialist centers restrict current market development.

Middle East and Africa

The Middle East and Africa accounted for an estimated 4%, or USD 25.27 million. Consanguinity can increase the occurrence of selected recessive disorders in parts of the Middle East, but reliable subtype-level prevalence is limited. Gulf countries provide the strongest access to genetic testing and specialist care. Across Africa, diagnostic capacity and rehabilitation access remain the main constraints.

Competitive Landscape

The competitive landscape is organized by genotype rather than broad disease label. BridgeBio is closest to potential commercialization with BBP-418 for FKRP-related LGMD2I/R9. AskBio is developing an AAV gene-replacement approach for the same subtype. Atamyo targets LGMD2C/R5 with ATA-200 and maintains other LGMD programs. Sarepta’s portfolio includes SRP-9003 for LGMD2E/R4 and additional sarcoglycan and LGMD targets.

An oral chronic therapy and one-time gene therapy may eventually compete within the same subtype, but their eligibility, risk, durability and pricing profiles will differ. Early market leadership will depend on genetic diagnosis, center activation, evidence across ambulatory and non-ambulatory patients, manufacturing capacity and payer acceptance.

BridgeBio Pharma, Inc.

BridgeBio is developing BBP-418, an oral ribitol-based glycosylation-substrate therapy for LGMD2I/R9 caused by FKRP variants. The therapy is designed to enhance residual FKRP function and restore alpha-dystroglycan glycosylation. It is a chronic oral treatment rather than an AAV gene therapy, creating a distinct administration and safety profile.

In the Phase 3 FORTIFY interim analysis, BridgeBio reported improvement across motor, biomarker and pulmonary endpoints compared with placebo. The company stated that BBP-418-treated participants completed the 100-meter timed test 31 seconds faster than placebo recipients at 12 months. On May 27, 2026, FDA accepted the NDA with Priority Review and set November 27, 2026 as the target action date. The near-term competitive position depends on regulatory approval, labeling, payer coverage and launch identification of genetically confirmed patients.

Atamyo Therapeutics SAS

Atamyo is a Généthon spin-off developing AAV gene therapies for muscular dystrophies and cardiomyopathies. ATA-200 is a single-dose intravenous gene therapy that carries a functional human SGCG gene for LGMD2C/R5. The Phase 1b/2 study evaluates safety, pharmacodynamics, efficacy and immunogenicity in children.

Atamyo presented results from the first treated patients at the May 2026 ASGCT meeting. The program addresses a pediatric population that can lose ambulation before adulthood and develop cardiac disease. Atamyo’s competitive strength is subtype expertise and access to Généthon’s research base. Its challenges are small-patient recruitment, systemic AAV safety, durable expression and manufacturing scale.

Asklepios BioPharmaceutical, Inc.

AskBio, a Bayer subsidiary, is developing AB-1003, also called LION-101, for FKRP-related LGMD2I/R9. The candidate uses an AAV-based gene-replacement strategy and is being evaluated in the Phase 1/2 LION-CS101 trial. Unlike BBP-418’s chronic substrate approach, AB-1003 aims to deliver a functional gene through a one-time infusion.

AB-1003 has received FDA orphan-drug and rare-pediatric-disease designations. AskBio brings capsid, promoter and Pro10 manufacturing capabilities to the program. Its competitive position depends on clinical safety, muscle expression, functional durability and eligibility relative to an oral therapy that may reach the market earlier.

Sarepta Therapeutics, Inc.

Sarepta’s LGMD portfolio includes SRP-9003, or bidridistrogene xeboparvovec, for beta-sarcoglycan-deficient LGMD2E/R4. The investigational therapy uses the rAAVrh74 vector and an MHCK7 promoter to deliver a full-length beta-sarcoglycan transgene to skeletal, diaphragm and cardiac muscle. The company also lists programs addressing other LGMD targets.

The FDA granted Platform Technology Designation to the viral vector used in SRP-9003 in June 2025. The designation can support development efficiency but does not constitute product approval. Sarepta’s gene-therapy experience and manufacturing platform are strategic assets, while class-wide safety scrutiny and program-specific regulatory requirements remain major risks.

Recent Developments: March 16–September 16, 2026

May 13, 2026: Atamyo presented early safety and efficacy observations from the first patients treated with ATA-200 in the LGMD-R5 Phase 1b/2 trial at the ASGCT annual meeting. The results support continued dose-escalation work but remain based on a small, open-label early cohort.

May 27, 2026: The FDA accepted BridgeBio’s NDA for BBP-418 in LGMD2I/R9 and granted Priority Review. The agency assigned a November 27, 2026 target action date and did not plan an advisory committee meeting at the time of the announcement.

June–September 2026: Clinical-trial records continued to list Sarepta’s SRP-9003 studies in LGMD2E/R4 and Atamyo’s ATA-200 study in LGMD2C/R5 as investigational programs. No LGMD gene therapy had received marketing approval during the review window.

No additional product approval with a verifiable date between March 16 and September 16, 2026 was identified in the primary sources reviewed. The BBP-418 FDA decision was scheduled after the reporting cutoff and is not presented as completed.

Strategic Takeaways

• Build commercial forecasts at genotype level because each therapy addresses only a defined LGMD subtype.
• Expand genetic confirmation and variant re-evaluation before launch to reduce the pool of undiagnosed eligible patients.
• Prepare neuromuscular centers for baseline motor, pulmonary and cardiac assessment as part of treatment authorization.
• Keep supportive care in the pathway after disease-modifying therapy because rehabilitation and complication surveillance remain necessary.
• Distinguish oral chronic treatment from one-time AAV therapy in pricing, adherence, safety and outcomes strategies.
• Use natural-history and registry data to interpret slow progression and strengthen payer evidence in small populations.
• Treat manufacturing consistency and long-term safety follow-up as core competitive capabilities for systemic gene therapy.

Market Overview

The Global limb girdle muscular dystrophy treatment market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.

The global limb girdle muscular dystrophy treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. A vast set of hereditary illnesses known as limb-girdle muscular dystrophies cause muscle loss and weakening (muscular dystrophy). To develop the illness (autosomal recessive inheritance), often both parents have to pass on the defective (inoperative) gene.

Government investments and research, particularly in developing economies, will continue to drive utilization of advanced technology for novel treatments such as gene therapy or corticosteroids for limb-girdle muscular dystrophy type 1 and type 2 and boost the global limb girdle muscular dystrophy treatment market. 

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers & Restraints

Growing collaborations and regulatory approvals 

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for limb girdle muscular dystrophy treatment owing to the rising research. Various collaborations, acquisitions and license agreement with technological advancements among different countries will be a crucial factor driving the growth of the market. 

On July 12, 2023, in order to create the first of its kind effective digital models for enhancing bioproduction produces in the area of gene therapy, Thales, a European developer in artificial intelligence for mission-critical systems, and Genethon, an innovator and leader in genetic therapy development and research for rare genetic diseases, are bringing together their expertise. Gene therapy treatment development is a very difficult, intricate, expensive, and time-consuming procedure. The reduction of production costs and time represents a significant challenge.

Additionally, on February 16, 2023, the limb-girdle muscular dystrophy (LGMD) medicine AB-1003 (also known as LION-101) has been given orphan drug designation by the European Commission (EC), according to Asklepios BioPharmaceutical, Inc., a fully owned and independently run subsidiary of Bayer AG.

Furthermore, the rising utilization of novel medicines and solutions for limb girdle muscular dystrophy. Rising muscular dystrophy cases and increasing utilization of several drugs along with research for innovative product development will be a major factor driving the growth of the limb girdle muscular dystrophy treatment market.

Side effects associated with the therapy  

Although they are still relatively new forms of medicine, genetic treatments offer the potential to treat a wide range of illnesses. Certain cancers, allergic reactions, or organ or tissue damage if an injection is involved are examples of potential dangers. Genetic medicines are currently more safer owing to recent developments. Early research indicated very substantial health hazards associated with gene therapy, including toxicity, inflammation, and malignancy.

Segment Analysis

The global limb girdle muscular dystrophy treatment market is segmented based on type, treatment, end user and region.

Limb-girdle muscular dystrophy type 2 type segment accounted for approximately 56% of market share 

Calpainopathy, also known as limb-girdle muscular dystrophy form 2A, is brought on by CAPN3 gene mutations. About 30% of cases of limb-girdle muscular dystrophy are Type 2A, which is also the most prevalent type. Dysferlinopathy is also known as limb-girdle muscular dystrophy form 2B and is brought on by DYSF gene mutations. 

Initial symptoms of LGMD2A include frequently weakness and wastage (loss of muscular mass) in the shoulder, hip, and thigh muscles. Leg involvement is apparent earlier shoulder and arm involvement, and this weakness typically affects each side of the body equally. 

On September 19, 2023, ATA-200, a gene therapy for type 2C/R5 limb-girdle muscular dystrophy (LGMD2C/R5) that is related to -sarcoglycan (SGCG), was the subject of a Clinical Trial Application (CTA) filed in Europe by Atamyo Therapeutics, a biotechnology company specializing in the creation of new-generation gene treatments targeting neuromuscular diseases. The business also said that ATA-200 has been approved for non-dilutive funding from France 2030, a public program run by Bpifrance, in the amount of up to €8 million ($8.6 million), to support their clinical trial and industrial development projects. 

Geographical Penetration

North America accounted for around 39% of market share in 2022

Due to the rising need for limb girdle muscular dystrophy treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for limb girdle muscular dystrophy treatment.

Increasing expenditure on healthcare, advancement of technologies and different types of medications for several diseases, along with increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of limb girdle muscular dystrophy treatment market share of this region. The market in this area is growing as people become more aware of various novel treatments. The aforementioned elements attest to North America's hegemonic position in the world.

North America continues to be a key player in the global limb girdle muscular dystrophy treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for limb girdle muscle medications in the United States have been proactive in executing several initiatives or surgical procedures, stimulating these medications demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global limb girdle muscular dystrophy treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of corticosteroid or small molecule, was significantly impacted. The widespread lockdowns and restrictions imposed by the pandemic, which began in early 2020, had an effect on a number of initiatives all around the world.  

Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for limb girdle muscular dystrophy treatment. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global limb girdle muscular dystrophy treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for novel treatments.

Key Developments

• On August 3, 2023, the initial participant in the Phase 1 / Phase 2 LION-CS101 research study for people having limb-girdle muscular dystrophy subtype 2I/R9 (LGMD2I/R9) was recently dosed, according to Asklepios BioPharmaceutical, Inc., a genetic therapy company that is entirely owned and independently run as a subsidiary of Bayer AG. A brand-new FKRP replacement gene therapy under research is called AB-1003 (also referred to as LION-101).
• On June 22, 2023, the FDA accelerated the authorization of delandistrogene moxeparvovec-rokl (ELEVIDYS), an adeno-associated virus-based gene therapy, which is intended for the management of ambulatory children and adolescents with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene, according to Sarepta Therapeutics, Inc., the pioneer in precision genetic therapy for rare diseases. Based on the levels of ELEVIDYS micro-dystrophin seen in ELEVIDYS-treated patients, this indication was given accelerated approval. 

Competitive Landscape

The major global players in the market include Jubilant Cadista Pharmaceuticals Inc., Sarepta Therapeutics, Inc., ML Bio Solutions, Genethon, Asklepios BioPharmaceutical, Inc., Atamyo Therapeutics, Vita Therapeutics, Inc., Edgewise Therapeutics, BridgeBio Inc. and Hansa Biopharma.

Why Purchase the Report?

• To visualize the global limb girdle muscular dystrophy treatment market segmentation based on type, treatment, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of limb girdle muscular dystrophy treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global limb girdle muscular dystrophy treatment market report would provide approximately 61 tables, 57 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies